Medication info
Anarika Capsule 75 mg (Pregabalin)

Anarika Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Aju Pharmaceuticals Co., Ltd.
Appearance
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or pale yellow.
Packaging
Domestic - 30 capsules/bottle, Export - 30 capsules/box [10 capsules/PTP*3], Export - 100 capsules/box [10 capsules/PTP*10]
Approval status
Active

MFDS item code 201109277 · Approved 2011.10.31 · Insurance code 654004050

Summary

Main use
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medication is administered orally, regardless of food, in 2 divided doses of the total daily dose of pregabalin. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Aju Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve pain caused by peripheral and central neuropathy in adults. It is also utilized as an adjunctive treatment for partial seizures in patients with epilepsy, either with or without secondary generalized symptoms. Additionally, it is effective in reducing muscle pain and discomfort due to fibromyalgia. This way, it helps to manage various neurological disorders and pain, contributing to the improvement of patients' quality of life.

How to take

Adult dose

This medication is administered orally, regardless of food, in 2 divided doses of the total daily dose of pregabalin. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with Renal Impairment After systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. For women, multiply the result obtained from the above equation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so any symptoms or mood changes should be reported to healthcare professionals immediately during treatment. This medication should not be used by those who are allergic to its ingredients, and patients with specific genetic conditions such as lactose intolerance should also avoid it. Patients with diabetes should be cautious as weight gain from this medication may require adjustment of blood sugar control medication doses. If symptoms of angioedema, such as swelling of the face or around the mouth, appear due to hypersensitivity, the medication should be stopped immediately. Elderly patients may be at risk of falling or injury due to dizziness or drowsiness from this medication, so they should be especially careful during initial dosing. Some patients may experience blurred vision or changes in eyesight, and if such symptoms appear, they should consult healthcare professionals. There may be cases where other antiepileptic drugs are stopped before using this medication, but there is insufficient data on this, so caution should be taken in administration. Abrupt discontinuation of the medication can lead to withdrawal symptoms such as insomnia, headache, anxiety, depression, and suicidal thoughts, so it should be tapered off gradually under medical supervision. Due to the risk of drug abuse, patients with a history of mental illness or drug abuse should be particularly cautious, and monitoring for unusual behavior is necessary. Patients with renal impairment may need dose adjustments, and those with heart disease should also be treated with caution. Caution is advised when using this medication with opioid analgesics, as central nervous system depression may be more pronounced. Drowsiness and dizziness may occur during treatment, so it is advisable to avoid driving or operating dangerous machinery. Early in pregnancy, there is a risk of fetal malformations, so pregnant women are advised not to take this medication, and women of childbearing age should use effective contraception. Breastfeeding women should consider stopping breastfeeding or discontinuing this medication, as it can be excreted in breast milk and affect the infant. In case of an overdose, confusion, drowsiness, seizures, etc., may occur, and immediate medical attention should be obtained. This medication should be kept out of reach of children, and transferring it to another container may lead to quality deterioration or accidents, so it should be avoided.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • swelling around the mouth
  • upper airway swelling
  • dizziness
  • drowsiness
Show 201 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • thoughts of suicide
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • appetite loss
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • paraphilia
  • restlessness
  • anxiety
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • impaired coordination
  • balance disorders
  • amnesia
  • attention deficits
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • drowsiness syndrome
  • cognitive impairment
  • nystagmus
  • speech disorders
  • abdominal cramps
  • reflex impairment
  • movement abnormalities
  • psychomotor agitation
  • positional dizziness
  • hyperesthesia
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • movement disorder
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tearing
  • eye irritation
  • mydriasis
  • during vibrations
  • changes in visual depth perception
  • strabismus
  • visual brightness
  • dizziness
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • bradycardia
  • benign tachycardia
  • benign arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • uterine cramps
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast hypertrophy
  • peripheral edema
  • edema
  • gait disturbances
  • falls
  • feeling drunk
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • elevated alanine aminotransferase
  • increased serum creatine phosphokinase
  • elevated aspartate aminotransferase
  • elevated blood sugar levels
  • decreased platelet count
  • reduced serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • fatigue
  • delirium
  • paralysis
  • affective disorder
  • drowsiness
  • confusion
  • agitation
  • restlessness
  • seizures.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is best to store it at room temperature between 15 and 30 degrees Celsius. This storage will help maintain the efficacy of the medication.

Appearance and packaging

Appearance

A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or pale yellow.

Package unit

Domestic - 30 capsules/bottle, Export - 30 capsules/box [10 capsules/PTP*3], Export - 100 capsules/box [10 capsules/PTP*10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.